


Substitute for form 1449A/PTO			Complete If Known		
			Application Number	09/723,713	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Filing Date	November 27, 2000	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1632	
			Examiner Name	Wehbe, A. M. S.	
			Attorney Docket Number	15270J-004741US	
Sheet	1	of	6		

U.S. PATENT DOCUMENTS+						
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number Kind Code ² (if known)				
[Handwritten Mark]	578	6,875,434	04-05-2005	Schenk		
	577	6,866,849	03-15-2005	Schenk		
	575	6,866,850	03-15-2005	Schenk		
	576	6,818,218	11-16-2004	Schenk		
	583	2004/0265919 A1	12-30-2004	Vanderstichlele et al.		
	581	2004/0247612 A1	12-09-2004	Wang		
	582	2004/0241164 A1	12-02-2004	Bales et al.		
	572	6,761,888	07-13-2004	Schenk		
	573	6,743,427	06-01-2004	Schenk		
	642	5,702,906	12-30-1997	Rosenthal		
	584	5,589,154	12-31-1996	Anderson		
	574	5,576,184	11-19-1996	Better et al.		
	619	5,530,101	06-25-1996	Queen et al.		

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	585	WO	04/080419	A2	09-23-2004			
	579	WO	04/031400	A2	04-15-2004			
	571	WO	04/013172	A2, A3	02-12-2004			
	586	WO	03/077858	A2, A3	09-25-2003			
	633	WO	96/08665	A2	03-21-1996			
	630	WO	95/17085	A1	06-29-1995			
	587	JP	7-165799	A	06-27-1995			abst. only
	632	JP	07-132033	A	05-23-1995			abst. only
	631	JP	62-267297	A	11-19-1987			abst. only

Examiner Signature	[Signature]	Date Considered	11/6/06
--------------------	-------------	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

60612115

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/723,713
				Filing Date	November 27, 2000
				First Named Inventor	Schenk, Dale B.
				Art Unit	1632
				Examiner Name	Wehbe, A. M. S.
Sheet	2	of	6	Attorney Docket Number	15270J-004741US




NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
no	588	ANDERSON, J. P., "Exact cleavage site of Alzheimer amyloid precursor in neuronal PC-12 cells," <u>Neuroscience Letters</u> , 128(1):126-128 (1991).	
	589	ANDERSON, M. W., "Amending the amyloid hypothesis," <u>The Scientist</u> , 18(20):28-29 (2004).	
	590	BACSKAI et al., "Non-Fc-mediated mechanisms are involved in clearance of amyloid- β in vivo by immunotherapy," <u>J. Neurosci.</u> , 22(18):7873-7878 (2002).	
	639	Chimicon International, "Mouse Anti-Amyloid Beta Protein Monoclonal Antibody," Catalog # MAB1561	
	591	CHROMY et al., "Self-assembly of A β (1-42) into globular neurotoxins," <u>Biochemistry</u> , 42(44):12749-12760 (2003).	
	592	CITRON et al., "Evidence that the 42- and 40- amino acid forms of amyloid- β protein are generated from the β -amyloid precursor protein by different protease activities," <u>PNAS</u> , 93(23):13170-13175 (1996).	
	593	CITRON, M., "Alzheimer's disease: treatments in discovery and development," <u>Nat. Neurosci.</u> , 5:1055-1057 (2002).	
	594	DEMATTOS et al., "Brain to plasma amyloid- β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease," <u>Science</u> , 295(5563):2264-2267 (2002).	
	595	DODART et al., "Immunization reverses memory deficits without reducing brain A β burden in Alzheimer's disease model," <u>Nat. Neurosci.</u> , 5(5):452-457 (2002).	
	596	DODEL et al., "Immunotherapy for Alzheimer's disease," <u>Lancet Neurol.</u> , 2(4):215-220 (2003).	
	597	DOVEY et al., "Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain," <u>J. Neurochem.</u> , 76(1):173-181 (2001).	
	598	DUFF et al., "Increased amyloid- β 42(43) in brains of mice expressing mutant presenilin 1," <u>Nature</u> , 383(6602):710-713 (1996).	


Examiner Signature		Date Considered	1/6/06
-----------------------	--	--------------------	--------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/723,713
				Filing Date	November 27, 2000
				First Named Inventor	Schenk, Dale B.
				Art Unit	1632
Examiner Name	Wehbe, A. M. S.				
Sheet	3	of	6	Attorney Docket Number	15270J-004741US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	599	ERIKSEN et al., "NSAIDs and enantiomers of flurbiprofen target γ -secretase and lower A β 42 in vivo," <u>J. Clin. Invest.</u> , 112(3):440-449 (2003).	
	600	FINDEIS, M. A., "Approaches to discovery and characterization of inhibitors of amyloid β -peptide polymerization," <u>Biochem. Biophys. Acta</u> , 1502(1):76-84 (2000).	
	601	FRENKEL et al., "Reduction of β -amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization," <u>Vaccine</u> , 21(11-12):1060-1065 (2003).	
	602	FRENKEL et al., "Towards Alzheimer's β -amyloid vaccination," <u>Biologicals</u> , 29(3-4):243-247 (2001).	
	603	GELINAS et al., "Immunotherapy for Alzheimer's disease," <u>PNAS</u> , 101(suppl. 2):14657-14662 (2004).	
	634	Genbank Accession number AAB48800, "Anti-DNA immunoglobulin light chain IgG [Mus musculus]," 09/14/01.	
	635	Genbank Accession number CAA46659, "IgE antibody light chain(VJ)," 06/15/93.	
	636	Genbank Accession number X65775.1, "M.musculus DNA for IgE antibody light chain (VJ)," 06/15/93.	
	637	Genbank Accession number AAD26773, "Immunoglobulin heavy chain VH3609-JH3 region [Mus musculus]," 04/22/99.	
	604	GONG et al., "Alzheimer's disease-affected brain: presence of oligomeric A β ligands (ADDLs) suggests a molecular basis for reversible memory loss," <u>PNAS</u> , 100(18):10417-10422 (2003).	
	605	GREENBERG et al., "Alzheimer disease's double-edged vaccine," <u>Nat. Med.</u> , 9(4):389-390 (2003).	
	606	HAASS, C., "New hope for Alzheimer disease vaccine," <u>Nat Med.</u> , 8(11):1195-1196 (2002).	


Examiner Signature		Date Considered	1/6/05
--------------------	---	-----------------	--------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/723,713
				Filing Date	November 27, 2000
				First Named Inventor	Schenk, Dale B.
				Art Unit	1632
Examiner Name	Wehbe, A. M. S.				
Sheet	4	of	6	Attorney Docket Number	15270J-004741US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
D	607	HOCK et al., "Generation of antibodies specific for β -amyloid by vaccination of patients with Alzheimer disease," <u>Nat. Med.</u> , 8(11):1270-1275 (2002).	
	608	IRIZARRY et al., "Alzheimer disease therapeutics," <u>J. Neuropathol. Exp. Neurol.</u> , 60(10):923-928 (2001).	
	609	JANUS et al., "Transgenic mouse models of Alzheimer's Disease," <u>Physiol. Behav.</u> , 73(5):873-886 (2001).	
	640	JUNG et al., "Alzheimer's Beta-amyloid Precursor Protein Is Expressed on the Surface of Immediately Ex Vivo Brain Cells: a Flow Cytometric Study," <u>J. Neurosci. Res.</u> , 46:336-348 (1996).	
	628	KOFLER et al., "Mechanism of Allergic Cross-Reactions--III. cDNA Cloning and Variable-Region Sequence Analysis of Two IgE Antibodies Specific for Trinitrophenyl," <u>Mol. Immunology</u> , 29(2):161-166 (1992).	
	627	KRISHNAN et al., "Correlation Between the Amino Acid Position of Arginine in VH-CDR3 and Specificity for Native DNA Among Autoimmune Antibodies ^{1,2} ," <u>J. Immunol.</u> , 157(6):2430-2439 (1996).	
	610	MATTSON et al., "Good and bad amyloid antibodies," <u>Science</u> , 301(5641):1845-1849 (2003).	
	611	MCLAURIN et al., "Therapeutically effective antibodies against amyloid- β peptide target amyloid- β residues and 4-10 and inhibit cytotoxicity and fibrillogenesis," <u>Nat Med.</u> , 8(11):1263-1269 (2002).	
	612	MONSONEGO et al., "Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer's disease," <u>J. Clin. Invest.</u> , 112(3):415-422 (2003).	
	613	MONSONEGO et al., "Immunotherapeutic approaches to Alzheimer's disease," <u>Science</u> , 302(5646):834-838 (2003).	
	614	PAGANETTI et al., "Amyloid precursor protein truncated at any of the γ -secretase sites is not cleaved to β -amyloid," <u>J. Neurosci. Res.</u> , 46(3):283-293 (1996).	


Examiner Signature		Date Considered	1/6/00
--------------------	---	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/723,713
				Filing Date	November 27, 2000
				First Named Inventor	Schenk, Dale B.
				Art Unit	1632
				Examiner Name	Wehbe, A. M. S.
Sheet	5	of	6	Attorney Docket Number	15270J-004741US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
W	615	PALLITTO et al., "Recognition sequence design for peptidyl modulators of β -amyloid aggregation and toxicity," <u>Biochemistry</u> , 38(12):3570-3578 (1999).	
	616	PFEIFER et al., "Cerebral hemorrhage after passive anti-A β immunotherapy," <u>Science</u> , 298(5597):1379 (2002).	
	641	RACKE et al., "Exacerbation of Cerebral Amyloid Angiopathy-Associated Microhemorrhage in Amyloid Precursor Protein Transgenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of amyloid β ," <u>J. Neurosci.</u> , 25(3):629-636 (2005).	
	638	Research Corporation Technology News, "THP and SangStat Partner to Develop Humanized Polyclonal Antibody Drugs," 11/11/02.	
	626	"Researchers Develop Blood Test to Diagnose Alzheimer's- Type Changes in Mice," downloaded from www.businesswire.com on 12/15/04.	
	617	SCHMID, R. E., "Study suggest Alzheimer vaccine fix," from www.msnbc.com/news, pages 1-5 (2002).	
	629	SEIDL et al., "Predominant V _H genes expressed in innate antibodies are associated with distinctive antigen-binding sites," <u>PNAS</u> , 96:2262-2267 (1999).	
	618	SELKOE, D. J., "Alzheimer's disease is a synaptic failure," <u>Science</u> , 298(5594):789-791 (2002).	
	622	SERGEANT et al., "Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach," <u>J. Neurochem.</u> , 85(6):1581-1591 (2003).	
	620	SOLOMON, B., "Generation and brain delivery of anti-aggregating antibodies against β -amyloid plaques using phage display technology," <u>J. Neural Transm. Suppl.</u> , 62:321-325 (2002).	
	621	SOLOMON, B., "Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease," <u>DNA and Cell Biology</u> , 20(11):697-703 (2001).	
	623	WALSH et al., "Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo," <u>Nature</u> , 416(6880):535-539 (2002).	

Examiner Signature		Date Considered	1/6/06
-----------------------	---	--------------------	--------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.


Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/723,713
				Filing Date	November 27, 2000
				First Named Inventor	Schenk, Dale B.
				Art Unit	1632
				Examiner Name	Wehbe, A. M. S.
Sheet	6	of	6	Attorney Docket Number	15270J-004741US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	624	WASHINGTON UNIVERSITY IN ST. LOUIS SCHOOL OF MEDICINE, "Study gives Clues to Working of Anti-Alzheimer Antibody," downloaded from www.medicine.wustl.edu/~wumpa/news on 12/15/04.	
	625	WHITE et al., "Immunotherapy as a therapeutic treatment for neurodegenerative disorders," <u>J. Neurochem.</u> , 87(4):801-808 (2003).	
	580	ZLOKOVIC et al., "Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers," <u>PNAS</u> , 93(9):4229-4334 (1996) abstract only.	

Examiner Signature		Date Considered	1/6/06
-----------------------	--	--------------------	--------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



"Express Mail" Label No. EV 732 173 514 US

Date of Deposit October 19, 2005

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.510 on the date indicated above and is addressed to:

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

By: 

Susan J. Johnson

PATENT

Attorney Docket No.: 15270J-004741US

Client Reference No.: 209-US-CIP5C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Dale B. Schenk

Application No.: 09/723,713

Filed: November 27, 2000

For: PREVENTION AND TREATMENT
OF AMYLOIDOGENIC DISEASE

Examiner: Anne Marie Sabrina Wehbe

Art Unit: 1632

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on the attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of the non U.S. Patent references can be found in Application No. 09/322,289, filed May 28, 1999 (Attorney Docket No. 15270J-004740US). It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.


Applicant also cites commonly owned copending applications directed to related subject matter:

09/201,430 filed 11/30/98 issued as U.S. 6,787,523 on 09/07/04;





09/497,553 filed 02/03/00;
09/724,477 filed 11/28/00 issued as U.S. 6,787,143 on 09/07/04;
09/723,927 filed 11/28/00 issued as U.S. 6,787,138 on 09/07/04;
09/723,762 filed 11/28/00 issued as U.S. 6,787,144 on 09/07/04;
09/724,102 filed 11/28/00 issued as U.S. 6,787,139 on 09/07/04;
09/724,489 filed 11/28/00 issued as U.S. 6,787,140 on 09/07/04;
10/816,022 filed 03/31/04 issued as U.S. 6,866,850 on 03/15/05;
10/816,529 filed 03/31/04 issued as U.S. 6,818,218 on 11/16/04;
10/815,391 filed 03/31/04 issued as U.S. 6,866,849 on 03/15/05;
10/934,818 filed 09/02/04;
10/934,609 filed 09/02/04 issue fee paid 01/24/05;
10/933,559 filed 09/02/04 issue fee paid 01/24/05;
10/934,819 filed 09/02/04;
10/815,353 filed 03/31/04 issued as U.S. 6,808,712 on 10/26/04;
10/816,380 filed 03/31/04 issue fee paid 01/24/05;
10/815,404 filed 03/31/04 issue fee paid 11/12/04;
09/322,289 filed 05/28/99;
09/723,713 filed 11/27/00;
09/723,760 filed 11/27/00;
09/724,319 filed 11/27/00;
09/723,384 filed 11/27/00 issued as U.S. 6,710,226 on 03/23/04;
09/724,495 filed 11/27/00;
10/788,666 filed 02/27/04;
10/429,216 filed 05/30/03;
10/828,548 filed 04/19/04;
10/923,471 filed 08/20/04;
10/923,474 filed 08/20/04;
10/928,926 filed 08/27/04;
10/923,605 filed 08/20/04;
10/923,267 filed 08/20/04;



10/923,469 filed 08/20/04;
09/580,015 filed 05/26/00;
09/724,940 filed 11/28/00 issue fee paid 11/12/04;
09/724,961 filed 11/28/00 issued as U.S. 6,743,427 on 06/01/04;
09/580,018 filed 05/26/00 issued as U.S. 6,761,888 on 07/13/04;
09/724,552 filed 11/28/00 issued as U.S. 6,750,324 on 06/15/04;
09/723,544 filed 11/28/00;
09/724,273 filed 11/28/00;
09/724,551 filed 11/28/00 issued as U.S. 6,787,637 on 09/07/04;
09/724,288 filed 11/28/00;
10/777,792 filed 02/11/04;
10/890,024 filed 04/12/04;
10/889,999 filed 04/12/04;
10/890,000 filed 07/12/04;
10/890,070 filed 07/12/04;
10/890,071 filed 07/12/04;
09/580,019 filed 05/26/00;
09/723,765 filed 11/28/00;
09/724,291 filed 11/28/00;
10/822,968 filed 04/12/04;
09/724,929 filed 11/28/00;
09/724,567 filed 11/28/00 issued as U.S. 6,890,535 on 05/10/05;
09/724,575 filed 11/28/00;
09/724,953 filed 11/28/00 issued as U.S. 6,875,434 on 04/05/05;
09/724,570 filed 11/28/00 issue fee paid 02/10/05;
09/585,656 filed 06/01/00;
09/723,766 filed 11/27/00;
09/723,725 filed 11/27/00;
09/579,690 filed 05/26/00;
09/979,701 filed 03/13/01 (U.S. Nat'l Stage of PCT/US00/14810 filed 05/26/00);

09/979,952 filed 04/09/02 (U.S. Nat'l Stage of PCT/US00/15239 filed 06/01/00);
issued as U.S. 6,913,745 on 07/05/05; and,


09/980,568 filed 03/12/02 (U.S. Nat'l Stage of PCT/US00/15302 filed 06/01/00).

Applicant also cites the following copending applications directed to related
subject matter but subject to different assignment:

10/010,942 filed 12/06/01;
10/789,273 filed 02/27/04;
10/232,030 filed 08/30/02;
10/010,942 filed 12/06/01;
10/388,389 filed 03/12/03;
10/703,713 filed 11/07/03;
10/704,070 filed 11/07/03;
10/388,214 filed 03/12/03;
10/858,855 filed 06/01/04;
10/771,174 filed 02/04/04.
60/622,525 filed 10/26/04;
60/636,684 filed 12/15/04;
60/636,842 filed 12/15/04;
60/637,253 filed 12/16/04;
60/636,810 filed 12/15/04;
60/637,138 filed 12/16/04;
60/636,776 filed 12/15/04;
60/636,687 filed 12/15/04.


Applicant further cites the following commonly owned abandoned applications
directed to related subject matter:

60/067,740 filed 12/02/97;
60/080,970 filed 04/07/98;
60/067,219 filed 12/03/97;
60/079,697 filed 03/27/98;




09/204,838 filed 12/03/98;
09/724,921 filed 11/28/00;
09/724,929 filed 11/28/00;
60/137,010 filed 06/01/99;
60/251,892 filed 12/06/00;
60/137,047 filed 06/01/99;
60/136,655 filed 05/28/99; and
09/723,544 filed 11/28/00.

Applicant also cites the following abandoned application directed to related subject matter but subject to different assignment:



60/251,892 filed 12/06/00;
60/474,654 filed 05/30/03;
60/530,481 filed 12/17/03;
60/444,150 filed 02/01/03; and,
60/363,751 filed 03/12/02.

Applicant points out that the following applications are now commonly assigned but were previously subject to different assignment than the present application:



60/067,219 filed 12/03/97;
60/079,697 filed 03/27/98;
09/204,838 filed 12/03/98;
09/724,921 filed 11/28/00; and,
09/724,929 filed 11/28/00.

Applicant understands the Examiner can access papers from the prosecution of the cited cases electronically via PALM. However, if the Examiner has difficulty obtaining papers from that source he or she is invited to call the undersigned who will be happy to supply them.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant

information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance. Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Joe Liebeschuetz
Reg. No. 37,505

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
JOL:crf
60612115 v1